Ignite Creation Date:
2025-12-25 @ 4:56 AM
Ignite Modification Date:
2026-03-01 @ 3:20 AM
Study NCT ID:
NCT02358018
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2016-11-02
First Post:
2015-02-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Study Overview
Official Title:
68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial
Status:
NO_LONGER_AVAILABLE
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to use a new type of scan, called 68Ga-DOTATOC PET/CT scan, instead of OctreoScan, the standard scan, to diagnose, monitor and manage your tumor. 68Ga-DOTATOC is an improved imaging agent being routinely used in many centers outside the USA, with better tumor detection than with OctreoScan.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: